Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Chronic Active Antibody-mediated Rejection in Kidney Transplantation
NCT02201576Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2015
- Primary completion
- Jul 2020
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in antibody-mediated transplant rejection (AMR), sponsored by Assistance publique - Hôpitaux de Paris. Started Feb 2015; status: completed.
02
Drugs
bortezomib
03
Conditions
antibody-mediated transplant rejection (AMR)
Beyond the preview
Go deeper on NCT02201576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201576.